Debt-Laden PharmEasy To Raise ₹2,400 Cr Through Right Issue At A 90% Discount
Discover PharmEasy’s bold strategy to raise INR 2,400 Cr through a heavily discounted right issue, navigating its debt challenges with determination.
How Did PharmEasy Make A Comeback With Positive Cash Flow?
In April 2023, PharmEasy recorded an adjusted EBITDA of Rs 16 crore and managed a positive cash flow. Read the blog to know more about it.
Reasons To Hold PharmEasy Unlisted Shares For The Long Term Ahead Its IPO
PharmEasy’s IPO has caused turbulence in its unlisted shares, making investors question the worth of holding them.
Understanding PharmEasy Current Performance In Pre-IPO Market
Get a complete overview of PharmEasy current performance in the Pre-IPO market. Also, discover why buying its unlisted shares is advantageous
